Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1272543 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL22445092 | 0.80 | CYP1A2 (0.47) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL7418624 | 0.77 | HPGD (0.57) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL1273009 | 0.77 | KMT2A (0.45) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL1273007 | 0.77 | KMT2A (0.45) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL8315368 | 0.73 | LMNA (0.50) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL15270800 | 0.73 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL24214309 | 0.73 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL10724996 | 0.73 | HDAC6 (0.53) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL30099741 | 0.73 | HDAC6 (0.53) | ALDH1A1SMN1; SMN2RAB9ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-7893093-B2 | Sulfonyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | disclosed |
| EP-1866277-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006102535-A2 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281879-A1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | ALDH1A1 2741/4885SMN1; SMN2 3606/4885RAB9A 1299/4885 |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | ALDH1A1 2741/4885SMN1; SMN2 3606/4885RAB9A 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.